keyword
MENU ▼
Read by QxMD icon Read
search

mCRPC

keyword
https://www.readbyqxmd.com/read/28440324/lutetium-177-labelled-anti-prostate-specific-membrane-antigen-antibody-and-ligands-for-the-treatment-of-metastatic-castrate-resistant-prostate-cancer-a-systematic-review-and-meta-analysis
#1
R J S Calopedos, V Chalasani, R Asher, L Emmett, H H Woo
BACKGROUND: Promising therapeutic results of the prostate-specific membrane antigen (PSMA) ligand have been shown when labelling with lutetium-177 ((177)Lu). We performed a systematic review and meta-analysis to assess the therapeutic response of (177)Lu-PSMA in the treatment of metastatic castration-resistant prostate cancer (mCRPC). METHODS: A systematic review was conducted using electronic databases up to December 2016. Two reviewers independently extracted data and assessed methodological quality...
April 25, 2017: Prostate Cancer and Prostatic Diseases
https://www.readbyqxmd.com/read/28440320/a-review-of-pomegranate-in-prostate-cancer
#2
REVIEW
C J Paller, A Pantuck, M A Carducci
BACKGROUND: Preclinical studies showing that pomegranate juice and its components inhibit prostate cancer led to multiple clinical trials to determine whether pomegranate products could slow the growth of prostate cancer. This review summarizes the preclinical data and discusses the results of the clinical trials. METHODS: Trials targeted patients on active surveillance, neoadjuvant patients, patients with biochemical recurrence (BCR) following local therapy for prostate cancer, and patients with metastatic castration-resistant prostate cancer (mCRPC)...
April 25, 2017: Prostate Cancer and Prostatic Diseases
https://www.readbyqxmd.com/read/28428880/long-term-complete-remission-with-ipilimumab-in-metastatic-castrate-resistant-prostate-cancer-case-report-of-two-patients
#3
Luc Cabel, Elika Loir, Gwenaelle Gravis, Pernelle Lavaud, Christophe Massard, Laurence Albiges, Giulia Baciarello, Yohann Loriot, Karim Fizazi
BACKGROUND: Prostate cancer is one of the most common cancers in men and the fourth leading cause of cancer mortality worldwide. Although major progress has been achieved in the last years for patients with metastatic castrate-resistant prostate cancer (mCRPC), thanks to next-generation androgen receptor axis targeted drugs, taxanes, and bone-targeted agents, immunotherapy has not been widely approved and used for the treatment of prostate cancer. Two large studies with ipilimumab, an anti-CTLA-4 (cytotoxic T-lymphocyte antigen 4) antibody reported improved progression-free survival, but not statistically improved overall survival at the primary analysis (CA184 043 and CA184 095)...
2017: Journal for Immunotherapy of Cancer
https://www.readbyqxmd.com/read/28427521/management-of-metastatic-castration-resistant-prostate-cancer-a-focus-on-radium-223-opinions-and-suggestions-from-an-expert-multidisciplinary-panel
#4
REVIEW
Sergio Baldari, Giuseppe Boni, Roberto Bortolus, Orazio Caffo, Giario Conti, Giuseppe De Vincentis, Fabio Monari, Giuseppe Procopio, Daniele Santini, Ettore Seregni, Riccardo Valdagni
Radium-223, a calcium mimetic bone-seeking radionuclide that selectively targets bone metastases with alpha particles, is approved for the treatment of men with metastatic castration-resistant prostate cancer (mCRPC) and symptomatic bone metastases. In patients with mCRPC, treatment with radium-223 has been associated with survival benefit, regardless of prior docetaxel use, and also has a positive impact on symptomatic skeletal events and quality of life. Radium-223 is best suited for patients with symptomatic mCRPC and bone-predominant disease and no visceral metastases, and may lead to better outcomes when given early in the course of the disease...
May 2017: Critical Reviews in Oncology/hematology
https://www.readbyqxmd.com/read/28426107/controversies-and-consensus-in-the-innovation-access-for-cancer-therapy-in-the-european-countries-on-the-subject-of-metastatic-prostate-cancer
#5
S Oudard, F Courbon
Innovative cancer therapies and advances in drug development have created new hopes for patients and health providers. The purpose of this article was to evaluate the discrepancies in the assessment of the magnitude of benefit of four new drugs (abiraterone acetate, enzalutamide, cabazitaxel, radium-223 dichloride) for the treatment of metastatic castration-resistant prostate cancer (mCRPC). The comparison was done among three European countries (UK, Germany and France) and Canada, according to the statement of each country and to the European Society of Medical Oncology (ESMO) Magnitude of Clinical Benefit Scale...
February 1, 2017: Annals of Oncology: Official Journal of the European Society for Medical Oncology
https://www.readbyqxmd.com/read/28415742/androgen-receptor-amplification-is-concordant-between-circulating-tumor-cells-and-biopsies-from-men-undergoing-treatment-for-metastatic-castration-resistant-prostate-cancer
#6
Jennifer Podolak, Kristi Eilers, Timothy Newby, Rachel Slottke, Erin Tucker, Susan B Olson, Hui-Wen Lue, Jack Youngren, Rahul Aggarwal, Eric J Small, Julie N Graff, Joshi J Alumkal, Tomasz M Beer, George V Thomas
Increased AR activity has been shown to be preserved in spatially distinct metastatic tumors from the same patient suggesting the requirement for lineage-specific dependencies for metastatic castration resistant prostate cancer (mCRPC). Amplification of the AR gene is a common mechanism by which mCRPC increase AR activity. To determine whether AR amplification in circulating tumor cells (CTC) could complement metastatic tissue biopsies in men undergoing treatment for mCRPC, we developed a novel two-step assay to isolate CTCs and subsequently analyzed AR amplification status in CTCs and matched biopsy tissue from the same patient by fluorescence in situ hybridization (FISH)...
March 13, 2017: Oncotarget
https://www.readbyqxmd.com/read/28408529/targeted-alpha-therapy-of-mcrpc-with-225-actinium-psma-617-dosimetry-estimate-and-empirical-dose-finding
#7
Clemens Kratochwil, Frank Bruchertseifer, Hendrik Rathke, Marcus Bronzel, Christos Apostolidis, Wilko Weichert, Uwe Haberkorn, Frederick Lars Giesel, Alfred Morgenstern
To develop a treatment protocol for (225)Ac-PSMA-617 alpha-radiation therapy in advanced stage, metastatic castration-resistant prostate cancer patients with PSMA-positive tumor phenotype. Methods: A dosimetry estimate was calculated based on time-activity-curves derived from serially performed (177)Lu-PSMA-617 scans extrapolated to the physical half-life of (225)Ac, assuming instant decay of instable daughter nuclides. Salvage therapies empirically conducted with 50kBq/kg (n = 4), 100kBq/kg (n = 4), 150kBq/kg (n = 2), 200kBq/kg (n = 4) (225)Ac-PSMA-617 were evaluated retrospectively regarding toxicity and treatment response...
April 13, 2017: Journal of Nuclear Medicine: Official Publication, Society of Nuclear Medicine
https://www.readbyqxmd.com/read/28401143/impact-of-abiraterone-acetate-with-and-without-prior-docetaxel-chemotherapy-on-the-survival-of-patients-with-metastatic-castration-resistant-prostate-cancer-a-population-based-study
#8
Joice Rocha, Armen G Aprikian, Marie Vanhuyse, Fabio L Cury, Jason Hu, Noémie Prévost, Alice Dragomir
BACKGROUND: Abiraterone acetate was introduced in Quebec in 2012 for the treatment of metastatic castration-resistant prostate cancer (mCRPC) in patients who had received chemotherapy with docetaxel. This study describes abiraterone use in the early postapproval period and its clinical effectiveness in Quebec, for both patients who had received docetaxel chemotherapy and those who could not receive docetaxel therapy owing to medical reasons. METHODS: A retrospective cohort study was conducted using Quebec public health care administrative databases...
January 2017: CMAJ Open
https://www.readbyqxmd.com/read/28395931/impact-of-abiraterone-acetate-and-enzalutamide-on-symptom-burden-of-patients-with-chemotherapy-naive-metastatic-castration-resistant-prostate-cancer
#9
S Salem, M Komisarenko, N Timilshina, L Martin, R Grewal, S Alibhai, A Finelli
AIMS: Treatments and disease burden of metastatic castration-resistant prostate cancer (mCRPC) considerably affect a patient's quality of life. However, patient-reported symptom burden data are still largely insufficient. This study sought to compare the self-reported symptom burden of men with chemotherapy-naive (CN) mCRPC treated with abiraterone acetate (AA) or enzalutamide (EZ) in routine clinical practice. MATERIALS AND METHODS: Between 2011 and 2015, 189 CN-mCRPC patients who had received AA (n = 76) or EZ (n = 113) at the Princess Margaret Cancer Centre were included...
April 8, 2017: Clinical Oncology: a Journal of the Royal College of Radiologists
https://www.readbyqxmd.com/read/28392429/-management-of-a-progressing-prostate-cancer-results-of-a-national-study
#10
F Rozet, M Roupret, C Hennequin, C Massard, P Blanchard, S Le Moulec
INTRODUCTION: The introduction of new treatments in metastatic castration resistant prostate cancer (mCRPC) requires a close follow-up to detect a progression and then to adapt the treatment. In that context, a national survey was proposed to a group of experts and the aim was to identify the modalities of surveillance in different clinical situations. METHODS: A questionnaire was sent to 1464 urologists, medical oncologists and radiotherapists, about a clinical case; it was about a patient presenting a prostate cancer, evolving from a biologic progression after radical prostatectomy to a situation of metastasis resistant to the castration...
April 6, 2017: Progrès en Urologie
https://www.readbyqxmd.com/read/28390646/first-line-management-of-metastatic-castrate-resistant-prostate-cancer-patients-audit-of-real-life-practices
#11
Anthony Turpin, David Pasquier, Christophe Massard, Jean-François Berdah, Stéphane Culine, Nicolas Penel
BACKGROUND: No reliable guidelines are available for choosing the best option between docetaxel and new hormonal therapies (NHTs) (i.e., abiraterone and enzalutamide) in first-line therapy for metastatic castration-resistant prostate cancer (mCRPC) patients. We performed an audit of real-life practices. METHODS: We built an online questionnaire and distributed it with the help of French oncology networks. This questionnaire was sent to 481 physicians who treat patients with mCRPC...
April 5, 2017: Bulletin du Cancer
https://www.readbyqxmd.com/read/28383088/extraction-of-223-radium-by-haemodialysis-after-treatment-of-metastatic-castration-resistant-prostate-cancer
#12
Oliver Stephan Großer, Heiko Wissel, Thekla Wallbaum, Philipp Genseke, Dennis Kupitz, Jens Ricke, Juri Ruf, Holger Amthauer
AIM: (223)Radium-dichloride ((223)Ra) administration is an upcoming therapeutic option in patients with castration-resistant metastatic prostate cancer (mCRPC), whose renal and faecal excretion of (223)Ra has been primarily estimated from data of a phase-I clinical trial in patients with normal renal function. In the rare case of concomitant renal insufficiency requiring haemodialysis (HD), an estimation of the contamination of dialysate would be beneficial. METHODS: The excretion of (223)Ra and its concentration in the dialysate in a patient with mCRPC and end-stage renal disease was examined for six consecutive treatment cycles...
April 6, 2017: Nuklearmedizin. Nuclear Medicine
https://www.readbyqxmd.com/read/28370882/safety-and-efficacy-of-2-weekly-cabazitaxel-in-metastatic-castration-resistant-prostate-cancer
#13
A Clément-Zhao, M Auvray, H Aboudagga, F Blanc-Durand, A Angelergues, Y A Vano, F Mercier, N El Awadly, B Verret, C Thibault, S Oudard
OBJECTIVES: To evaluate the safety and efficacy of a 2-weekly cabazitaxel schedule in metastatic castration-resistant prostate cancer (mCRPC) patients. MATERIALS AND METHODS: From October 2013 to February 2016, 43 mCRPC patients were treated with cabazitaxel (16 mg/m(2) on days 1 and 15 of a 4-week cycle) with G-CSF support. The safety profile and efficacy (prostate-specific antigen [PSA] response; biological, clinical or radiological progression-free survival [PFS] and overall survival [OS]) were analyzed...
March 28, 2017: BJU International
https://www.readbyqxmd.com/read/28367230/efficacy-of-cabazitaxel-treatment-in-metastatic-castration-resistant-prostate-cancer-in-second-and-later-lines-an-experience-from-two-german-centers
#14
Stefanie Zschäbitz, Sonia Vallet, Boris Hadaschik, Daniel Debatin, Stefan Fuxius, Andreas Karcher, Sascha Pahernik, Cathleen Spath, Stefan Duensing, Dirk Jäger, Markus Hohenfellner, Carsten Grüllich
Purpose: Several new treatment options for patients with metastatic castration resistant prostate cancer (mCRPC) have been approved within the last years - among them cabazitaxel (CAB), abiraterone acetate, enzalutamide, and radium-223. The aim of this study was to assess factors predictive for efficacy of CAB. Methods: We analyzed all patients with mCRPC treated with CAB at our institutions between 2011 and 2016. Data were retrieved retrospectively from the electronical patient chart. Results: 69 patients received CAB (26...
2017: Journal of Cancer
https://www.readbyqxmd.com/read/28366592/patients-preferences-for-the-treatment-of-metastatic-castrate-resistant-prostate-cancer-a-discrete-choice-experiment
#15
Lina Eliasson, Hayley M de Freitas, Lindsay Dearden, Brian Calimlim, Andrew J Lloyd
PURPOSE: Patient treatment preferences are increasingly being used to inform health care decision making. This discrete choice experiment assessed how men perceive the risks and benefits of hypothetical treatment options for metastatic castrate-resistant prostate cancer (mCRPC). METHODS: Treatment attributes for inclusion were identified through a review of the literature and product labels. Expert interviews confirmed clinical appropriateness and patient relevance of the attributes, which included effectiveness (delay in months before chemotherapy), steroid use, possible drug interactions (additional hospital visits for monitoring), fogginess (effects on cognition and memory), fatigue (extreme tiredness), food restrictions, and bone pain...
March 30, 2017: Clinical Therapeutics
https://www.readbyqxmd.com/read/28365706/metastasiertes-kastrationsresistentes-prostatakarzinom-grunds%C3%A3-tzliche-therapieoptionen-und-progression
#16
David Pfister
In der Entwicklung des Prostatakarzinoms spielen Androgene und der Androgenrezeptor eine zentrale Rolle. Über Jahrzehnte war die konventionelle Androgendeprivationstherapie (ADT) die wichtigste Behandlungsoption im metastasierten Stadium. Trotz initialen Ansprechens auf eine ADT entwickelt sich im Verlauf in der Regel ein metastasiertes kastrationsresistentes Prostatakarzinom (mCRPC). Für dieses Stadium gab es jahrelang keine Therapie, für die eine Verlängerung des Überlebens gezeigt werden konnte. Dies änderte sich erst 2004 mit der Studie TAX 327 zur Wirksamkeit von Docetaxel...
2017: Oncology Research and Treatment
https://www.readbyqxmd.com/read/28365705/abirateronacetat-beim-metastasierten-kastrationsresistenten-prostatakarzinom-wann-beginnen
#17
Kurt Miller
Für die Therapie des metastasierten kastrationsresistenten Prostatakarzinoms (mCRPC) stehen inzwischen mehrere moderne Wirkstoffe zur Verfügung. Sie verdrängen zunehmend die aufgrund mangelnder Alternativen lange Jahre üblichen sekundären Hormonmanipulationen, denn neuere Substanzen konnten - im Gegensatz zu den konventionellen antihormonellen Therapien - das Überleben in Phase-III-Studien verlängern. So ist der Beginn der mCRPC-Therapie gemäß Leitlinie der European Association of Urology in den letzten Jahren im Krankheitsverlauf nach vorne gerückt...
2017: Oncology Research and Treatment
https://www.readbyqxmd.com/read/28361167/potential-drug-drug-interactions-with-abiraterone-in-metastatic-castration-resistant-prostate-cancer-patients-a-prevalence-study-in-france
#18
Clément Bonnet, Pascaline Boudou-Rouquette, Esther Azoulay-Rutman, Olivier Huillard, Jean-Louis Golmard, Edith Carton, Gaëlle Noé, Michel Vidal, Galdric Orvoen, Anne Chah Wakilian, Clémentine Villeminey, Benoit Blanchet, Jérôme Alexandre, François Goldwasser, Audrey Thomas-Schoemann
PURPOSE: Abiraterone acetate combined with prednisone improves survival in metastatic castration-resistant prostate cancer (mCRPC) patients. This oral anticancer agent may result in drug-drug interactions (DDI). We aimed to evaluate the prevalence of DDI with abiraterone and the possible determinants for the occurrence of these DDI. METHODS: We performed a single centre retrospective review from electronic medical records of mCRPC patients treated with abiraterone from 2011 to 2015...
March 30, 2017: Cancer Chemotherapy and Pharmacology
https://www.readbyqxmd.com/read/28361045/phase-i-clinical-trial-of-sipuleucel-t-combined-with-escalating-doses-of-ipilimumab-in-progressive-metastatic-castrate-resistant-prostate-cancer
#19
Mark Scholz, Sabrina Yep, Micah Chancey, Colleen Kelly, Ken Chau, Jeffrey Turner, Richard Lam, Charles G Drake
BACKGROUND: Sipuleucel-T (SIP-T), which functions by stimulating cancer-specific dendritic cells, prolongs survival in men with prostate cancer. Ipilimumab (IPI) achieved a borderline survival advantage in a large randomized trial. SIP-T and IPI are potentially synergistic. PATIENTS AND METHODS: Nine men with progressive metastatic castrate-resistant prostate cancer (mCRPC) were treated prospectively with SIP-T followed immediately by IPI with one of the following doses of IPI: 1 mg/kg at 1 week after SIP-T; 1 mg/kg at 1 and 4 weeks after SIP-T; or 1 mg/kg at 1, 4, and 7 weeks after SIP-T...
2017: ImmunoTargets and Therapy
https://www.readbyqxmd.com/read/28348171/the-identification-of-macrophage-enriched-glycoproteins-using-glycoproteomics
#20
Jelani C Zarif, Weiming Yang, James R Hernandez, Hui Zhang, Kenneth J Pienta
Prostate cancer is a leading cause of cancer-related deaths of men in the U.S. While localized disease is highly treatable by surgical resection and radiation, cancer that has metastasized remains incurable. Immune cells that primarily scavenge debris, promote prostate cancer angiogenesis and wound repair are M2 Macrophages. They are phenotypically similar to M2 tumor-associated macrophages (M2-TAMs) have been reported to associate with solid tumors and aide in proliferation, metastasis, and resistance to therapy...
March 27, 2017: Molecular & Cellular Proteomics: MCP
keyword
keyword
85742
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"